Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis

Molecular Cancer

Review

Valerie C. Wasinger¹  Yujin Lee²  Peter Graham²  Yong Li²  Jie Ni²  Julia Beretov³ 

[1] Bioanalytical Mass Spectrometry Facility, Mark Wainwright Analytical Centre, UNSW Sydney, 2052, Kensington, NSW, Australia;School of Medical Science, UNSW Sydney, 2052, Kensington, NSW, Australia;St. George and Sutherland Clinical Campuses, School of Clinical Medicine, UNSW Sydney, 2052, Kensington, NSW, Australia;Cancer Care Centre, St. George Hospital, 2217, Kogarah, NSW, Australia;St. George and Sutherland Clinical Campuses, School of Clinical Medicine, UNSW Sydney, 2052, Kensington, NSW, Australia;Cancer Care Centre, St. George Hospital, 2217, Kogarah, NSW, Australia;Anatomical Pathology, NSW Health Pathology, St. George Hospital, 2217, Kogarah, NSW, Australia;

关键词: Breast cancer;    Extracellular vesicles;    Liquid biopsy;    Biomarker;    Diagnosis;    Prognosis;   

DOI  :  10.1186/s12943-023-01741-x

 received in 2022-10-04, accepted in 2023-02-06,  发布年份 2023

来源: Springer

【 摘 要 】

Current clinical tools for breast cancer (BC) diagnosis are insufficient but liquid biopsy of different bodily fluids has recently emerged as a minimally invasive strategy that provides a real-time snapshot of tumour biomarkers for early diagnosis, active surveillance of progression, and post-treatment recurrence. Extracellular vesicles (EVs) are nano-sized membranous structures 50–1000 nm in diameter that are released by cells into biological fluids. EVs contain proteins, nucleic acids, and lipids which play pivotal roles in tumourigenesis and metastasis through cell-to-cell communication. Proteins and miRNAs from small EVs (sEV), which range in size from 50–150 nm, are being investigated as a potential source for novel BC biomarkers using mass spectrometry-based proteomics and next-generation sequencing. This review covers recent developments in sEV isolation and single sEV analysis technologies and summarises the sEV protein and miRNA biomarkers identified for BC diagnosis, prognosis, and chemoresistance. The limitations of current sEV biomarker research are discussed along with future perspective applications.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

13731_2023_266_Article_IEq10.gif

13731_2023_266_Article_IEq6.gif

Fig. 1

Fig. 9